Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON29736
NL-OMON29736Not yet recruitingNot Applicable

B-UVB phototherapy versus Excimerlaser after minigrafting in vitiligo patients - NB-UVB versus Excimerlaser after minigrafting

Academisch Medisch Centrum0 sites24 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
24
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •i. Consecutive patients, diagnosed with stable vitiligo vulgaris* with symmetrical vitiligo patches
  • •*Vitiligo vulgaris: a few to many widespread depigmented macules over the entire body, with often a symmetrically distribution pattern.
  • •Stable means: no expansion of existing lesions or appearance of new lesions during the previous 6 months, absence of Koebner*s phenomenon and a positive minigrafting test
  • •ii. Patients, eligible for minigrafting and NB-UVB/excimer therapy
  • •iii. Adult patients: * 18 years
  • •iv. Patients who have given written informed consent

Exclusion Criteria

  • •i. With a history of hypertrophic scarring and/or keloid
  • •ii History of allergic/phototoxic reaction (Lidocaine, Tegaderm, Suture strips, sunlight)
  • •iii With a negative minigrafting test
  • •iv With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member)
  • •v. With a personal history of photosensitivity and/or phototoxicity disorders
  • •vi. With skin type I (according to Fitzpatrick classification I-VI)
  • •vii. Who are pregnant
  • •viii. Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s)
  • •ix. With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema.
  • •x. Who are not able to have 2 times weekly NB-UVB/Excimer therapy.
  • •xi. With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weekswill be required.

Investigators

Similar Trials

Completed
Not Applicable
B-UVB phototherapy versus excimer laser after minigrafting in vitiligo patients.
NL-OMON29475none24
Completed
Not Applicable
B-UVB phototherapy versus Excimer laser after mini-grafting in vitiligo patientsVitiligoSkin and Connective Tissue DiseasesPigmentation disorder
ISRCTN68425813Academic Medical Center (AMC) (The Netherlands)14
Recruiting
Phase 3
Evaluation of the efficacy of oral N- acetylcysteine in the treatment of vitiligo patientsvitiligo disease.Vitiligo
IRCT20210729052013N1Iran University of Medical Sciences40
Completed
Phase 3
Effect of Needling with intralesional synacthen injection in treatment of vitiligovitiligo.
IRCT20190515043600N1Esfahan University of Medical Sciences78
Completed
Phase 2
Effect of narrow band UVB phototherapy plus betamethasone ointment versus narrow band UVB phototherapy plus placebo ointment on the treatment of vitiligoVitiligo.Vitiligo
IRCT201402269014N26Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences30